ALUMIS INC
ALMSNASDAQTrading Snapshot
- Day Range
- $6.97 – $7.25
- 52-Week Range
- $4.39 – $31.35
- Volume (shares)
- 343,159.335
- Avg Volume (shares)
- —
- Shares Outstanding
- 129.4M
- Next Earnings
- 2026-11-12
Fundamentals Snapshot
- Annual Revenue
- $24M
- Last Q Revenue
- $2M
- P/E Ratio
- -1.8
- P/S Ratio
- 120.7x
- EPS (TTM)
- $-3.44
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +94.8%
ALUMIS INC
ALMS
StockOtter · stockotter.spaceAbout ALUMIS INC
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
Alumis Inc. (NASDAQ:ALMS) Stock Has Consensus Target Price of $33.27
Alumis Inc. (NASDAQ: ALMS - Get Free Report) has earned an average recommendation of "Moderate Buy" from the fourteen ratings firms that are covering the company, MarketBeat Ratings reports. One investment analyst has ra
Alumis Announces New Phase 3 Data Demonstrating Envudeucitinib Rapidly and Durably Improved Psoriasis Burden Across Scalp, Itch, and Quality of Life Measures
– Results build on ONWARD3 highest complete skin clearance (54% PASI 100) at Week 48, reinforcing envudeucitinib's potential to become a leading oral therapy for moderate-to-severe plaque psoriasis – Patients switching f
Tango Therapeutics (NASDAQ:TNGX) vs. Alumis (NASDAQ:ALMS) Financial Analysis
Tango Therapeutics (NASDAQ: TNGX - Get Free Report) and Alumis (NASDAQ: ALMS - Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength
Alumis (NASDAQ:ALMS) & Pyxis Oncology (NASDAQ:PYXS) Head-To-Head Review
Pyxis Oncology (NASDAQ: PYXS - Get Free Report) and Alumis (NASDAQ: ALMS - Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the s
Financial Survey: Alvotech (NASDAQ:ALVO) & Alumis (NASDAQ:ALMS)
Alumis (NASDAQ: ALMS - Get Free Report) and Alvotech (NASDAQ: ALVO - Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength
Alumis Inc. (ALMS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Alumis Inc. (ALMS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript